Huamao Mark Lin - Concepedia

Author

Huamao Mark Lin

Takeda (United States)ORCID

Also Known As

H Mark Lin, H. Lin, H. M. Lin, H.M. Lin, Hongzhao Lin, Huamao Lin, Huamao M Lin, Huamao M. Lin, Huamao Mark Lin

103

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Takeda (United States)Millennium Engineering and Integration (United States)Dana-Farber Cancer Institute Seoul National University Hospital Royal Marsden Hospital

About

Huamao Mark Lin is an author at Takeda (United States) specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	320
2	Health Sciences	5	5	158
3	Immunology	5	5	149
4	Cell Biology	4	4	127
5	Pathology	4	4	82

Huamao Mark Lin

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, Journal of Clinical Oncology	2020	361
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, Journal of Thoracic Oncology	2021	350
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, JAMA Oncology	2021	282
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer Gerald S. Falchook, Robert L. Coleman, A. Roszak, JAMA Oncology	2018	88
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial David P. Dearnaley, Daniel R. Saltzstein, John E. Sylvester, European Urology	2020	71
Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life Rachid Baz, Huamao Mark Lin, Ai Hui, Supportive Care in Cancer Hematological MalignancyQuality Of LifeLife AssessmentOncologyHealth-related Quality	2015	67
Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer Mohammad Jahanzeb, Huamao Mark Lin, Xiaoyun Pan, Clinical Lung Cancer	2020	67
STAT-1 is activated by IL-4 and IL-13 in multiple cell types I.-Ming Wang, Huamao Mark Lin, Samuel J. Goldman, Molecular Immunology InflammationCytokineAutoimmune DiseaseImmune RegulationImmunology	2004	59
Signaling via LAT (linker for T-cell activation) and Syk/ZAP70 is required for ERK activation and NFAT transcriptional activation following CD2 stimulation Maria Paola Martelli, Huamao Mark Lin, Weiguo Zhang, Blood	2000	53
Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma Xavier Leleu, Tamás Masszi, Nizar J. Bahlis, American Journal of Hematology	2018	49

Page 1